S-TARget‘s first product candidate, SG100, is an active immunotherapy prototype to cure and prevent allergic asthma induced by house dust mite (HDM). It will be followed by other therapeutic vaccines against other allergens: S-TARget plans to develop successful prototypes for other allergic indications such as HDM-induced atopic eczema and hay fever.

S-TARget’s vaccines are designed to cure allergic diseases in less than 10 treatments over a 1-1.5 year period. Its therapies are expected to provide a clear cost advantage over established treatments for the healthcare system and result in significantly higher convenience for the patient due to shorter treatment cycles and permanent relief of disease symptoms in contrast to current treatments.